Tyra Biosciences, Inc. (NASDAQ:TYRA - Get Free Report) shares gapped up prior to trading on Monday . The stock had previously closed at $10.55, but opened at $11.44. Tyra Biosciences shares last traded at $10.89, with a volume of 87,825 shares traded.
Analysts Set New Price Targets
A number of brokerages recently issued reports on TYRA. HC Wainwright reiterated a "buy" rating and set a $30.00 target price on shares of Tyra Biosciences in a research report on Monday, March 31st. Piper Sandler began coverage on shares of Tyra Biosciences in a research report on Wednesday, May 21st. They set an "overweight" rating and a $33.00 price target on the stock. Finally, Wedbush restated an "outperform" rating and set a $30.00 price objective on shares of Tyra Biosciences in a report on Friday, March 28th. Six equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has a consensus rating of "Buy" and a consensus price target of $30.83.
Read Our Latest Research Report on TYRA
Tyra Biosciences Price Performance
The firm has a market cap of $548.42 million, a price-to-earnings ratio of -6.42 and a beta of 1.07. The business has a 50-day moving average of $9.50 and a 200-day moving average of $12.02.
Tyra Biosciences (NASDAQ:TYRA - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The company reported ($0.47) earnings per share for the quarter, topping the consensus estimate of ($0.49) by $0.02. As a group, equities analysts anticipate that Tyra Biosciences, Inc. will post -1.57 EPS for the current fiscal year.
Hedge Funds Weigh In On Tyra Biosciences
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. KLP Kapitalforvaltning AS bought a new position in shares of Tyra Biosciences during the fourth quarter worth approximately $31,000. US Bancorp DE bought a new stake in Tyra Biosciences during the fourth quarter worth $50,000. BNP Paribas Financial Markets bought a new stake in shares of Tyra Biosciences during the 4th quarter worth $60,000. Aquatic Capital Management LLC acquired a new stake in shares of Tyra Biosciences in the 4th quarter valued at approximately $64,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank acquired a new stake in Tyra Biosciences in the first quarter valued at approximately $84,000. 84.14% of the stock is owned by institutional investors.
About Tyra Biosciences
(
Get Free Report)
Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.
Featured Articles
Before you consider Tyra Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tyra Biosciences wasn't on the list.
While Tyra Biosciences currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
